Table 6.

Treatment drugs used in two patient cohorts

Groups parameters	SCD patient N = 39	Healthcare professionals N = 121	P-value
Antiviral treatment, n (%)	30 (76)	106 (88)	0.10
Antibacterial treatment, n (%),	13 (33)	15 (12)	0.003
Prophylactic LMWH, n (%),	16 (41)	11 (9)	< 0.0001
Salycilate, n (%),	11 (28)	1 (1)	< 0.0001
Corticosteroid, n (%),	4 (10)	6 (5)	0.15
Tocilizumab, n (%),	2 (5)	2 (2)	0.22
Convalescent plasma, n (%)	0	1(0.8)	N/A

LMWH, low molecular weight heparin